PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D change of 26.95% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
24.63%
G&A change of 24.63% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
26.14%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.90%. Jim Chanos would check for waste.
26.14%
Total costs growth exceeding 1.5x Biotechnology median of 0.95%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth exceeding 1.5x Biotechnology median of 1.52%. Jim Chanos would check for overinvestment.
-26.20%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while Biotechnology median is -1.88%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-26.43%
Pre-tax income decline while Biotechnology median is -1.38%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while Biotechnology median is -1.93%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while Biotechnology median is 2.31%. Seth Klarman would investigate causes.
-26.52%
Diluted EPS decline while Biotechnology median is 1.98%. Seth Klarman would investigate causes.
0.09%
Share count reduction exceeding 1.5x Biotechnology median of 0.70%. Joel Greenblatt would investigate strategy.
0.09%
Diluted share reduction exceeding 1.5x Biotechnology median of 0.82%. Joel Greenblatt would investigate strategy.